Amerikanische Gesellschaft für Hirudotherapie

Directorate General of Drug Administration

DGDA · Bangladesh · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Bangladesh's Directorate General of Drug Administration (under the Ministry of Health and Family Welfare) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general medical device framework or traditional medicine pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Bangladesh
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Bangladeshi national drug and medical device law
  • Bangladeshi framework for Unani, Ayurvedic, and homoeopathic practice as appropriate

Prescriber Requirements

  • Bangladesh Medical and Dental Council–registered physician — order required for any biomedical device application
  • Traditional Unani / Ayurvedic practitioners registered under the relevant statutory boards may have separate scope; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

DGDA registration as applicable; Bangla and English-language labelling. Standard cold-chain conditions.

Import/Export Rules

DGDA import licence requirements; Department of Livestock Services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Bangladesh has statutory recognition of Unani and Ayurvedic medicine via dedicated boards; leech use within those traditions has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.